Bimekizumab Improves HSSQ Skin Pain over 3 Years in HS: Data from BE HEARD EXT
Main Article Content
Keywords
HS
Abstract
Introduction Hidradenitis suppurativa (HS) is an inflammatory skin disease characterized by painful lesions that negatively impact patients’ quality of life. Treatment with bimekizumab (BKZ), a humanized IgG1 monoclonal antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, previously demonstrated clinically meaningful improvements in skin pain over 2 years. Here, we report proportions of patients with moderate to severe HS achieving pain outcomes with BKZ over 3 years.
Procedure Data were pooled from BE HEARD I&II (BHIⅈ NCT04242446/NCT04242498) and BE HEARD EXTENSION (BHEXT; NCT04901195). Data are reported for patients randomized to BKZ from BHI&II baseline entering BHEXT (BKZ Total).
Skin pain severity was assessed using the skin pain item of the HS Symptom Questionnaire (HSSQ), scored 0–10. Skin pain response (at least a 30% reduction and ≥1-point reduction from baseline score ≥3), distribution of HSSQ skin pain severity categories (no/mild: 0–2; moderate: 3–5; severe/very severe: 6–10), and HSSQ skin pain absolute and percentage change from baseline (CfB) are reported at Weeks 48/148 (observed case).
Results 556 patients randomized to BKZ at BHI&II baseline completed Week 48 and entered BHEXT.
Among patients with baseline pain score ≥3 (N=496), 72.2% (358/496) and 80.9% (262/324) achieved HSSQ skin pain response at Week 48 and 148, respectively. At baseline, 10.0% (55/551) of patients reported no/mild skin pain; at Week 48 and 148, the proportion of patients reporting no/mild skin pain increased to 51.7% (287/555) and 65.8% (237/360), respectively.
At Week 48/148, HSSQ skin pain scores decreased with a mean (standard deviation [SD]) absolute CfB of −3.0 (2.8) / −3.9 (2.9), representing a 48.0% (49.4) / 62.4% (52.3) decrease.
Conclusion Patients treated with bimekizumab over 3 years experienced clinically meaningful improvements in skin pain, as measured by HSSQ.
References
2. Adams R et al. Front Immunol 2020;11:1894
3. Orenstein LAV et al. Presented at SHSA 2024; 3000238
4. Kimball AB et al. Lancet 2024;403:2504–19
5. BE HEARD EXT: www.clinicaltrials.gov/study/NCT04901195
6. Ingram JR et al. Dermatol Ther (Heidelb) 2025;15:1093–111
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.